Pharmas Join To Build Inflammation Biomarkers In Alzheimer's, Depression

22 May 2018

• By Emily Hayes

Drug firms exploring link between inflammation and central nervous system disorders are now sharing resources through public/private Biomarkers Consortium project.

Brain decline and dementia or aging as memory loss concept for brain cancer decay or an Alzheimer's disease with old rusting mechanical gears and cog wheels in the shape of a human head with rust.

Against the backdrop of multiple trial failures, pharmas are joining forces to support a project by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to develop biosignatures for Alzheimer's disease and major depression, based on research about the role in inflammation in these conditions.

The Biomarkers Consortium is a not-for-profit group founded in 2006 by the Foundation for the National Institutes of Health, the...